Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia

Drugs

Volumn 75, Issue 15, 2015, Pages 1715-1724

  Ito, Matthew K ^a   Watts, Gerald F ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; PCSK9 INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR;

APHERESIS; ARTICLE; FAMILIAL HYPERCHOLESTEROLEMIA; GENETICS; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIFESTYLE MODIFICATION; LIPOPROTEIN APHERESIS; LIVER TRANSPLANTATION; PREVALENCE; BLOOD; DEFICIENCY; HYPERLIPOPROTEINEMIA TYPE II;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; RECEPTORS, LDL;

EID: 84945497118     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0466-y     Document Type: Article

References (51)

1. Hovingh GK, Davidson MH, Kastelein JJ, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013;34(13):962-71. doi: 10.1093/eurheartj/eht015.
2. Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63(19):1935-47. doi: 10.1016/j.jacc.2014.01.060.
3. Vishwanath R, Hemphill LC. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. J Clin Lipidol. 2014;8(1):18-28. doi: 10.1016/j.jacl.2013.11.002.
4. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol. 2014;171(3):309-25. doi: 10.1016/j.ijcard.2013.11.025.
5. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90. doi: 10.1093/eurheartj/eht273.
6. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146-57. doi: 10.1093/eurheartj/ehu274.
7. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262-8. doi: 10.1016/j.atherosclerosis.2012.02.019.
8. Widhalm K, Binder CB, Kreissl A, Aldover-Macasaet E, Fritsch M, Kroisboeck S, et al. Sudden death in a 4-year-old boy: a near-complete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. J Pediatrics. 2011;158(1):167. doi: 10.1016/j.jpeds.2010.06.027.
9. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3):133-40. doi: 10.1016/j.jacl.2011.03.001.
10. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clinical Invest. 1973;52(7):1544-68. doi: 10.1172/JCI107332.
11. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214-25. doi: 10.1038/ncpcardio0836.
12. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, National Lipid Association Expert Panel on Familial H. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S9-17. doi: 10.1016/j.jacl.2011.03.452.
13. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA. 1987;84(19):6919-23.
14. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Suppl):S172-7. doi: 10.1194/jlr.R800091-JLR200.
15. Tada H, Kawashiri MA, Ohtani R, Noguchi T, Nakanishi C, Konno T, et al. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Atherosclerosis. 2011;219(2):663-6. doi: 10.1016/j.atherosclerosis.2011.08.004.
16. Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2014. doi: 10.1093/eurheartj/ehu058.
17. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40-6. doi: 10.1016/S0140-6736(12)61731-0.
18. Gagne C, Gaudet D, Bruckert E, Ezetimibe Study G. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105(21):2469-75.
19. Graesdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2012;6(4):331-9. doi: 10.1016/j.jacl.2012.03.004.
20. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124(20):2202-7. doi: 10.1161/CIRCULATIONAHA.111.042523.
21. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998-1006. doi: 10.1016/S0140-6736(10)60284-X.
22. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113-20. doi: 10.1161/CIRCULATIONAHA.113.004678.
23. Writing Group M, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-215. doi: 10.1161/CIRCULATIONAHA.109.192667.
24. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev Aust Assoc Clin Biochem. 2004;25(1):49-68.
25. Moorjani S, Roy M, Torres A, Betard C, Gagne C, Lambert M, et al. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet. 1993;341(8856):1303-6.
26. Baum SJ, Sijbrands EJ, Mata P, Watts GF. The doctor's dilemma: challenges in the diagnosis and care of homozygous familial hypercholesterolemia. J Clin Lipidol. 2014;8(6):542-9. doi: 10.1016/j.jacl.2014.09.005.
27. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014;8(5):473-88. doi: 10.1016/j.jacl.2014.07.007.
28. Bertolini S, Pisciotta L, Rabacchi C, Cefalu AB, Noto D, Fasano T, et al. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis. 2013;227(2):342-8. doi: 10.1016/j.atherosclerosis.2013.01.007.
29. Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl. 2011;12(2):221-63. doi: 10.1016/j.atherosclerosissup.2011.06.001.
30. Ned RM, Sijbrands EJ. Cascade screening for familial hypercholesterolemia (FH). PLoS Curr. 2011;3:RRN1238. doi: 10.1371/currents.RRN1238.
31. Ito MK, McGowan MP, Moriarty PM, National Lipid Association Expert Panel on Familial H. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S38-45. doi: 10.1016/j.jacl.2011.04.001.
32. Crestor [prescribing information]. Wilmington: AstraZeneca Pharmaceuticals; 2012.
33. Lipitor [prescribing information]. New York: Pfizer, Inc; 2012.
34. Blazing MA, Giugliano RP, Delemos J, Cannon CP, Musliner T, Terkashovec AM, et al., editors. On-treatment analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). American Heart Association Scientific Sessions; 15-19 November 2014, Chicago; 2014.
35. Kroon AA, van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 2000;152(2):519-26.
36. Thompson GR, Group H-ULAW. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198(2):247-55. doi: 10.1016/j.atherosclerosis.2008.02.009.
37. Juxtapid [prescribing information]. Cambridge: Aegerion Pharmaceuticals, Inc.; 2013.
38. Kynamro [prescribing information]. Cambridge: Genzyme Corporation; 2013.
39. Repatha [summary of product characteristics]. Breda: Amgen, Inc.; 2015.
40. Praluent [prescribing information]. Bridgewater: Sanofi and Regeneron Pharmaceuticals, Inc.; 2015.
41. Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: orphan and rare diseases, orphan drugs and orphan patients. World J Methodol. 2014;4(3):163-88. doi: 10.5662/wjm.v4.i3.163.
42. Hussain MM, Rava P, Walsh M, Rana M, Iqbal J. Multiple functions of microsomal triglyceride transfer protein. Nutr Metab. 2012;9:14. doi: 10.1186/1743-7075-9-14.
43. Burnett JR, Watts GF. MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises? Expert Opin Ther Targets. 2007;11(2):181-9. doi: 10.1517/14728222.11.2.181.
44. King TA, Patel G, Dutta S, Korb S, Wade JR, Foulds P, et al. Evaluation of the effects of the weak CYP3A4 inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. Atherosclerosis. 2015;241(1):e203.
45. Cuchel M, Bloom DJ, Averna MR, Meagher EA, du Toit Theron H, Sirtori CR, et al., editors. Sustained LDL-C lowering and stable hepatic fat levels in patients with homozygous familial hypercholesterolemia treated with the microsomal triglyceride transfer protein inhibitor, lomitapide: results of an ongoing long-term extension study. Annual Meeting of the American Heart Association; 16-20 November 2013, Dallas.
46. Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol. 2013;76(2):269-76. doi: 10.1111/j.1365-2125.2012.04469.x.
47. Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126(19):2283-92. doi: 10.1161/CIRCULATIONAHA.112.104125.
48. Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J. 2015;36:566-75. doi: 10.1093/eurheartj/eht549.
49. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341-50. doi: 10.1016/S0140-6736(14)61374-X.
50. Lambert G, Chatelais M, Petrides F, Passard M, Thedrez A, Rye KA, et al. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab. J Am Coll Cardiol. 2014;64(21):2299-300. doi: 10.1016/j.jacc.2014.07.995.
51. Kassim SH, Li H, Bell P, Somanathan S, Lagor W, Jacobs F, et al. Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. Hum Gene Ther. 2013;24(1):19-26. doi: 10.1089/hum.2012.108.